Monitoring oral antiplatelet therapy: Is it justified?

Therapeutic Advances in Cardiovascular Disease

Volumn 2, Issue 6, 2008, Pages 485-496

  Ang, Lawrence ^a   Mahmud, Ehtisham ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCSD MEDICAL CENTER   (United States)

Author keywords

Antiplatelet medications; Platelet function assay; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PRASUGREL; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE;

ACUTE HEART INFARCTION; ANALYZER; BLEEDING; BLOOD CLOTTING PARAMETERS; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; FLOW CYTOMETRY; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY;

ADMINISTRATION, ORAL; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; DRUG MONITORING; HUMANS; PLATELET AGGREGATION INHIBITORS;

EID: 68749102514     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944708094736     Document Type: Review

References (50)

1. Aleil, B., Meyer, N., Cazenave, J.P., Mossard, J.M. and Gachet, C. (2005) High stability of blood samples for flow cytometric analysis of VASP phsphorylation to measure the clopidogrel responsiveness in patients with coronary artery disease. Thromb Haemost 94: 886-887.
2. Ang, L., Palakodeti, V., Tsimikas, S., Khalid, A., Bromberg-Marin, G., Idrees, Z. et al. (2007) Elevated fibrinogen, higher body mass index and diabetes mellitus are associated with lower platelet inhibition in patients treated with clopidogrel. J Am Coll Cardiol 49: 387A.
3. Angiolillo, D.J., Bernardo, E., Sabate, M., Jimenez-Quevedo, P., Costa, M.A., Palazuelos, J. et al. (2007) Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 50: 1541-1547.
4. Angiolillo, D.J., Fernandez-Ortiz, A., Bernardo, E., Barrera Ramirez, C., Sabate, M., Fernandez, C. et al. (2004) Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 16: 325-329.
5. Blindt, R., Stellbrink, K., de Taeye, A., Muller, R., Kiefer, P., Yagmur, E. et al. (2007) The significance of vasodilator-simulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 98: 1329-1334.
6. Bonello, L., Camoin-Jau, L., Arques, S., Boyer, C., Panagides, D., Wittenberg, O. et al. (2008) Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 51: 1404-1411.
7. Buchanan, M.R., Schwartz, L., Bourassa, M., Brister, S.J., Peniston, C.M. and Brat Investigators. (2000) Results of the BRAT study-a pilot study investigating the possible significance of ASA nonresponsiveness on the benefits and risk of ASA on thrombosis in patients undergoing coronary artery bypass surgery. Can J Cardiol 16: 1385-1390.
8. Buonamici, P., Marcucci, R., Migliorini, A., Gensini, G.F., Santini, A., Paniccia, R. et al. (2007) Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 49: 2312-2317.
9. Cairns, J.A., Gent, M., Singer, J., Finnie, K.J., Froggatt, G.M., Holder, D.A. et al. (1985) Aspirin, Sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 313: 1369-1375.
10. Campo, G., Valgimigli, M., Gemmati, D., Percoco, G., Catozzi, L., Frangione, A. et al. (2007) Poor responsiveness for clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study. J Am Coll Cardiol 15: 1132-1137.
11. CAPRIE Steering Committee (2005) A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329-1339.
12. Cattaneo, M. (2007) Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost 5: 230-237.
13. Craft, R.M., Chavez, J.J., Snider, C.C., Muenchen, R.A. and Carroll, R.C. (2005) Comparison of modified Thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients. J Lab Clin Med 145: 309-315.
14. Dalen, J.E. (2007) Aspirin resistance: is it real? Is it clinically significant? Am J Med 120: 1-4.
15. Di Chiara, J., Bliden, K.P., Tantry, US, Hamed, M.S., Antonino, M.J., Suarez, T.A. et al. (2007) The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 56: 3014-9.
16. Dyszkiewicz-Korpanty, A.M., Frenkel, E.P. and Sarode, R. (2005) Approach ot the assessment of platelet function: comparison between optical-based platelet-rich plasma and impedance-based whole blood platelet aggregation methods. Clin Appl Thromb Hemost 11: 25-35.
17. Dziewierz, A., Dudek, D., Heba, G., Rakowski, T., Mielecki, W. and Dubiel, J.S. (2005) Inter-individual variability in response to clopidogrel in patients with coronary artery disease. Kardiol Pol 62: 108-117.
18. Eikelboom, J.W., Hirsh, J., Weitz, J.I., Johnston, M., Yi, Q. and Yusuf, S. (2002) Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105: 1650-1655.
19. Geisler, T., Langer, H., Wydymus, M., Gohring, K., Zurn, C., Bigalke, B. et al. (2007) Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 27: 2420-2425.
20. Gurbel, P.A., Becker, R.C., Mann, K.G., Steinhubl, S.R. and Michelson, A.D. (2007) Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 50: 1822-1834.
21. Gurbel, P.A., Bliden, K.P., Hiatt, B.L. and O'Connor, C.M. (2003) Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107: 2908-2913.
22. Hobson, A.R., Agarwala, R.A., Swallow, R.A., Dawkins, K.D. and Curzen, N.P. (2006) Thrombelastography: current clinical applications and its potential role in interventional cardiology. Platelets 17: 509-518.
23. Hochholzer, W., Trenk, D., Bestehorn, H.P., Fischer, B., Valina, C.M., Ferenc, M. et al. (2006) Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48: 1751-1754.
24. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2: 349-360.
25. Ivandic, B.T., Giannitsis, E., Schlick, P., Stanitz, P., Katus, H.A. and Hohlfeld, T. (2007) Determination of aspirin responsiveness by use of whole blood platelet aggregometry. Clin Chem 53: 614-619.
26. Jakubowski, J.A., Payne, C.D., Li, Y.G., Farid, N.A., Brandt, J.T., Small, D.S. et al. (2008) A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost 99: 215-222.
27. King III, S.B., Smith Jr, S.C., Hirshfeld Jr, J.W., Jacobs, A.K., Morrison, D.A., Williams, D.O. et al. (2008) 2007 Focused Update of the ACC/AHA/ SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Reivew New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 117: 261-295.
28. Krasopoulos, G., Brister, S.J., Beattie, W.S. and Buchanan, M.R. (2008) Aspirin “resistance” and risk of CV morbidity: systematic review and meta-analysis. BMJ 336: 195-198.
29. Lennon, M.J., Gibbs, M.N., Weightman, W.M., McGuire, D. and Michalopoulos, N. (2004) A comparison of PlateletworksTM and platelet aggregometry for the assessment of aspirin-related platelet dysfunction in cardiac surgical patients. J Cardiothorac Vasc Anesth 18: 135-140.
30. Lev, E.I., Patel, R.T., Maresh, K.J., Guthikonda, S., Granada, J., de Lao, T. et al. (2006) Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47: 27-33.
31. Lordkipanideze, M., Pharand, C., Schampaert, E., Turgeon, J., Palisaitis, D.A. and Diodati, J.G. (2007) A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 28: 1702-1708.
32. Mahmud, E. and Ang, L. (2006) Monitoring antiplatelet therapy during peripheral vascular and coronary interventions. Tech Vasc Interv Radiol 9: 56-63.
33. Mehta, S.R., Yusuf, S., Peters, R.J., Bertrand, M.E., Lewis, B.S., Natarajan, M.K. et al.; Clopidogrel in Unstable Angina to prevent Recurrent Events trial (CURE) investigators, (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358: 527-533.
34. Michelson, A.D. (2004) Platelet function testing in cardiovascular diseases. Circulation 110: e489-e493
35. Michelson, A.D., Frelinger III, A.L. and Furman, M.I. (2006) Current options in platelet function testing. Am J Cardiol 98: 4N-10N.
36. Moliterno, D.J. and Campbell, C.L. (2007) Unraveling questions surrounding clopidogrel resistance and stent thrombosis: one less snag. J Am Coll Cardiol 49: 2312-2317.
37. Muller, C., Buttner, H.J., Petersen, J. and Roskamm, H. (2000) A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 101: 590-593.
38. Nguyen, T.A., Diodati, J.G. and Pharand, C. (2005) Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 45: 1157-1164.
39. Paniccia, R., Antonucci, E., Gori, A.M., Marcucci, R., Giglioli, C., Antoniucci, D. et al. (2007) Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 5: 1839-1847.
40. Savi, P. and Herbrt, J.M. (2005) Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 31: 174-183.
41. Schwammenthal, Y., Tsabari, R., Shenkman, B., Schwartz, R., Matetzky, S., Lubetsk, A. et al. (2008) Aspirin responsiveness in acute brain ischaemia: association with stroke severity and clinical outcome. Cerebrovasc Dis 25: 355-361.
42. Serebruany, V.L., Steinhubl, S.R., Berger, P.B., Malinin, A.I., Bhatt, D.L. and Topol, D.J. (2005) Variability in platelet responseiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45: 246-251.
43. Storey, R.F. (2006) Biology and pharmacology of the platelet P2Y12 receptor. Current Pharmaceutical Design 12: 1255-1259.
44. The RISC Group (1990) Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 336: 827-830.
45. van Werkum, J.W., Hackeng, C.M., de Korte, F.I., Verheugt, F.W. and Ten Berg, J.M. (2007) Point-of-care platelet function testing in patients undergoing PCI: between a rock and a hard place. Neth Heart J 15: 299-305.
46. Wang, T.H., Bhatt, D.L. and Topol, E.J. (2006) Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 27: 647-654.
47. Wiviott, S.D., Braunwald, E., McCabe, C.H., Montalescot, G., Ruzyllo, W., Gottlieb, S. et al.; TRITON-TIMI 38 Investigators, (2007 a) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001-2015.
48. Wiviott, S.D., Trenk, D., Frelinger, A.L., O'Donoghue, M., Neumann, F.J., Michelson, A.D. et al.; PRINCIPLE-TIMI 44 Investigators, (2007 b) Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned
49. percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116: 2923-2932.
50. Yusuf, S., Zhao, F., Mehta, S.R., Chrolavicius, S., Tognoni, G. and Fox, K.K.; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial investigators. (2001) The CURE study. N Engl J Med 345: 494-502.